XV International Symposium on Atherosclerosis 2009

Program

Scope of the Symposium

Knowledge about the pathogenesis and biology of atherosclerosis as well as its prevention and treatment continues to rapidly expand. Many new advances in prediction, assessment of disease, and treatment have been made. In addition there has been a marked expansion in our understanding of the role of genetics and lifestyle in the pathogenesis of atherosclerosis and coronary heart disease, the leading cause of death and disability in developed and developing societies. There has also been a marked increase in the prevalence of obesity, metabolic syndrome, and diabetes, all of which are important for the pathogenesis of atherosclerosis, along with lipoprotein abnormalities (increased low density lipoproteins (LDL), remnant lipoproteins, and lipoprotein (a), and decreased high density lipoproteins (HDL). Ongoing advances in atherosclerotic research hold out the possibility of improved outcomes in patients assigned to low to moderate risk categories according to traditional risk assessment methods. Early detection strategies, including research into the genetic bases of atherosclerosis, advanced imaging techniques on both a macroscopic and molecular level, and identification of novel screening and diagnostic biomarkers, have the potential to enhance existing risk stratification methods and further reduce cardiovascular risk on a population level.

This meeting is designed to provide a comprehensive and up–to–date overview of recent advances in the field of atherosclerosis research, treatment, and prevention. It aims to provide a historical and scientific context for the efficacy of existing treatment modalities and to update health care professionals on best practices for cardiovascular risk reduction. It will also provide participants with insights into cutting–edge advances in the field and potential new therapeutic strategies, with the goal of further improving patient outcomes.